tetano
Editor, Senior Moderator
J Infect Chemother
. 2022 Mar 19;S1341-321X(22)00087-3.
doi: 10.1016/j.jiac.2022.03.008. Online ahead of print.
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate: A study of the 2017/18 and 2018/19 seasons and comparison with the 2011/12 to 2016/17 Japanese influenza seasons
Naoki Tani[SUP] 1 [/SUP], Naoki Kawai[SUP] 2 [/SUP], Hideyuki Ikematsu[SUP] 3 [/SUP], Takuma Bando[SUP] 4 [/SUP], Norio Iwaki[SUP] 4 [/SUP], Yoshio Takasaki[SUP] 5 [/SUP], Shizuo Shindo[SUP] 6 [/SUP], Yong Chong[SUP] 7 [/SUP], Seizaburo Kashiwagi[SUP] 4 [/SUP]
Affiliations
Abstract
Introduction: Large scale investigation of the clinical effectiveness of neuraminidase inhibitors for circulating influenza viruses are important along with the surveillance of virus susceptibility in vitro.
Methods: The duration of fever and other influenza symptoms as markers of the clinical effectiveness of laninamivir octanoate hydrate (laninamivir) were investigated in the Japanese 2017/18 and 2018/19 influenza seasons and compared with the results of the previous six seasons.
Results: Influenza A(H1N1)pdm09, A(H3N2), and B were found in 14, 45, and 52 patients in the 2017/18 season and in 22, 62, and 0 in the 2018/19 season, respectively. The median duration of fever for B was significantly longer than for A(H1N1)pdm09 and A(H3N2) in the 2017/18 season (p = 0.0461) and for A(H3N2) than for A(H1N1)pdm09 in the 2018/19 season (p = 0.0290). However, the differences were subtle in both seasons for other symptoms, with no significant differences in their median duration in comparison of the circulating types/subtypes. Over the eight seasons with the previous six seasons added, the median durations of fever were consistently longer for B than for A, but the relation between the A subtypes was inconsistent. The median durations of fever were comparable over the eight seasons for the virus types/subtypes, as were the median durations of other symptoms. The percentage of febrile patients decreased in a similar pattern over the eight seasons for each type/subtype.
Conclusions: The results confirmed that laninamivir has continued to be clinically effective against all types/subtypes of influenza viruses, with no safety issues.
Keywords: Fever; Influenza; Laninamivir; Neuraminidase inhibitor; Symptom.
. 2022 Mar 19;S1341-321X(22)00087-3.
doi: 10.1016/j.jiac.2022.03.008. Online ahead of print.
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate: A study of the 2017/18 and 2018/19 seasons and comparison with the 2011/12 to 2016/17 Japanese influenza seasons
Naoki Tani[SUP] 1 [/SUP], Naoki Kawai[SUP] 2 [/SUP], Hideyuki Ikematsu[SUP] 3 [/SUP], Takuma Bando[SUP] 4 [/SUP], Norio Iwaki[SUP] 4 [/SUP], Yoshio Takasaki[SUP] 5 [/SUP], Shizuo Shindo[SUP] 6 [/SUP], Yong Chong[SUP] 7 [/SUP], Seizaburo Kashiwagi[SUP] 4 [/SUP]
Affiliations
- PMID: 35317975
- DOI: 10.1016/j.jiac.2022.03.008
Abstract
Introduction: Large scale investigation of the clinical effectiveness of neuraminidase inhibitors for circulating influenza viruses are important along with the surveillance of virus susceptibility in vitro.
Methods: The duration of fever and other influenza symptoms as markers of the clinical effectiveness of laninamivir octanoate hydrate (laninamivir) were investigated in the Japanese 2017/18 and 2018/19 influenza seasons and compared with the results of the previous six seasons.
Results: Influenza A(H1N1)pdm09, A(H3N2), and B were found in 14, 45, and 52 patients in the 2017/18 season and in 22, 62, and 0 in the 2018/19 season, respectively. The median duration of fever for B was significantly longer than for A(H1N1)pdm09 and A(H3N2) in the 2017/18 season (p = 0.0461) and for A(H3N2) than for A(H1N1)pdm09 in the 2018/19 season (p = 0.0290). However, the differences were subtle in both seasons for other symptoms, with no significant differences in their median duration in comparison of the circulating types/subtypes. Over the eight seasons with the previous six seasons added, the median durations of fever were consistently longer for B than for A, but the relation between the A subtypes was inconsistent. The median durations of fever were comparable over the eight seasons for the virus types/subtypes, as were the median durations of other symptoms. The percentage of febrile patients decreased in a similar pattern over the eight seasons for each type/subtype.
Conclusions: The results confirmed that laninamivir has continued to be clinically effective against all types/subtypes of influenza viruses, with no safety issues.
Keywords: Fever; Influenza; Laninamivir; Neuraminidase inhibitor; Symptom.